Antiatherosclerotic and antiatherogenic effects of a calcium antagonist plus statin combination: Amlodipine and lovastatin

International Journal of Cardiology

Volumn 62, Issue SUPPL. 2, 1997, Pages

  Orekhov, Alexander N ^a   Tertov, Vladimir V ^a   Sobenin, Igor A ^a   Akhmedzhanov, Nadir M ^b   Pivovarova, Elena M ^a  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^b NATIONAL MEDICAL RESEARCH CENTER FOR THERAPY AND PREVENTIVE MEDICINE   (Russian Federation)

Author keywords

Amlodipine; Antiatherogenic effect; Antiatherosclerotic effect; Lovastatin; Modified low density lipoprotein

Indexed keywords

AMLODIPINE; ANTILIPEMIC AGENT; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME; VASCULAR SMOOTH MUSCLE;

AMLODIPINE; ANTICHOLESTEREMIC AGENTS; AORTA; ARTERIOSCLEROSIS; CALCIUM CHANNEL BLOCKERS; CELL DIVISION; CELLS, CULTURED; CHOLESTEROL; CULTURE MEDIA; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HUMANS; LIPID PEROXIDATION; LIPOPROTEINS, LDL; LOVASTATIN; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; TREATMENT OUTCOME;

EID: 0031593039     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(97)00243-X     Document Type: Conference Paper

References (43)

1. Blankenhorn D.H., Nessim S.A., Johnson R.L., Sanmarco M.E., Azen S.P., Cashin-Hemphill L. Beneficial effects of combined colestipol niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. J Am Med Assoc. 257:1987;3233-3240.
2. Watts G.F., Lewis B., Brunt J.N.H.et al. Effect on coronary artery disease of lipid-lowering diet and diet plus cholestyramine in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet. 339:1992;563-569.
3. MAAS investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633-638.
4. Jukema J.W., Bruschke A.V.G., van Boven A.J.et al. on behalf of the REGRESS study group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Statin Study (REGRESS). Circulation. 91:1995;2528-2540.
5. Kober G., Schneider W., Kaltenbach M. Can the progression of coronary sclerosis be influenced by calcium antagonists? J Cardiovasc Pharmacol. 13:1989;S2-S6.
6. Lichtlen P.R., Hugenholtz P.G., Rafflenbeul W., Hecker H., Jost S., Deckers J.W. on behalf of the INTACT group investigators. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Anti-atherosclerotic Therapy (INTACT). Lancet. 335:1990;1109-1113.
7. Waters D., Lesperance J., Francetich M.et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation. 82:1990;1940-1953.
8. Jukema J.W., Zwinderman A.H., van Boven A.J.et al. for the REGRESS study group. Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. Arterioscler Thromb Vasc Biol. 16:1996;425-430.
9. Orekhov AN, Tertov VV, Pivovarova EM. The effect of anti-hypertensive agents on atherosclerosis-related parameters of human aorta intimal cells. Cardiology (in press).
10. Orekhov A.N., Tertov V.V., Pokrovsky S.N.et al. Blood serum atherogenicity associated with coronary atherosclerosis. Evidence for nonlipid factor providing atherogenicity of low-density lipoproteins and an approach to its elimination. Circ Res. 62:1988;421-429.
11. Orekhov A.N., Tertov V.V., Kudryashov S.A., Smirnov V.N. Triggerlike stimulation of cholesterol accumulation and DNA and extracellular matrix synthesis induced by atherogenic serum or low density lipoprotein in cultured cells. Circ Res. 66:1990;311-320.
12. Orekhov A.N., Tertov V.V., Mukhin D.N., Mikhailenko I.A. Modification of low density lipoprotein by desialylation causes lipid accumulation in cultured cells. Discovery of desialylated lipoprotein with altered cellular metabolism in the blood of atherosclerotic patients. Biochem Biophys Res Commun. 162:1989;206-211.
13. Orekhov A.N., Tertov V.V., Mukhin D.N. Desialylated low density lipoprotein - naturally occurring modified lipoprotein with atherogenic potency. Atherosclerosis. 86:1991;153-161.
14. CPMP Working Party on Efficacy of Medicinal Products. EEC note for guidance: good clinical practice for trials on medicinal products in the European Community. Pharmacol Toxicol 1990;67:361-372.
15. Orekhov A.N., Tertov V.V., Kudryashov S.A., Khashimov K.A., Smirnov V.N. Primary culture of human aortic intima cells as a model for testing anti-atherosclerotic drugs. Effects of cyclic AMP, prostaglandins, calcium antagonists, antioxidants, and lipid-lowering agents. Atherosclerosis. 60:1986;101-110.
16. Hara A., Radin N.S. Lipid extraction of tissue with low-toxicity solvent. Anal Biochem. 90:1978;420-426.
17. Siedel J., Hagele E.O., Ziegenhorn J., Wahlefeld A.W. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem. 29:1983;1075-1080.
18. Lowry O.H., Rosenbrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem. 193:1951;265-275.
19. Lindgren FT. Preparative ultracentrifugal laboratory procedures and suggestions for lipoprotein analysis. In: Perkins EG, editor. Analysis of lipids and lipoproteins. New York: American Oil Chemical Society, 1975:205-224.
20. Vaskovsky V.E., Kostetsky E.Y., Vasendin I.M. A universal reagent for phospholipid analysis. J Chromatogr. 114:1975;129-137.
21. Esterbauer H., Striegl G., Puhl H., Rothender M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Rad Res Commun. 6:1989;67-75.
22. Yagi K. Lipid peroxidation. Assay for blood plasma and serum. Methods Enzymol. 105:1984;328-333.
23. Balla G., Jacob H.S., Eaton J.W., Belcher J.D., Vercelloti G.M. Hemin: a possible physiological mediator of low density lipoprotein oxidation and endothelial injury. Arteriocler Thromb. 11:1991;1700-1711.
24. Hashim S.A., Schuttinger G.M. Rapid determination of tocoferol in macro and microquantities of plasma. Am J Clin Nutr. 19:1966;137-147.
25. Habeeb A.F.S.A. Determination of free amino groups in proteins by trinitrobenzene sulfonic acid. Anal Biochem. 14:1966;328-336.
26. Warren L. The thiobarbituric acid assay of sialic acids. J Biol Chem. 234:1959;1971-1975.
27. Tertov V.V., Sobenin S.A., Orekhov A.N. Modified (desialylated) low-density lipoprotein measured in serum by lectin-sorbent assay. Clin Chem. 41:1995;1018-1021.
28. Tertov V.V., Sobenin I.A., Tonevitsky A.G., Orekhov A.N., Smirnov V.N. Isolation of atherogenic modified (desialylated) low density lipoprotein from blood of atherosclerotic patients: separation from native lipoprotein by affinity chromatography. Biochem Biophys Res Commun. 167:1990;1122-1127.
29. Rainwater D.L., Andres D.W., Ford A.L., Lowe W.F., Blanche P.J., Krauss R.M. Production of polyacrylamide gradient gels for the electrophoretic resolution of lipoproteins. J Lipid Res. 33:1992;1876-1881.
30. Wallenstein S., Zucker C.L., Fleiss J.L. Some statistical methods useful in circulation research. Circ Res. 47:1980;1-9.
31. Parmley W.W. Vascular protection from atherosclerosis: potential of calcium antagonists. Am J Cardiol. 66:1990;16I-22I.
32. Nayler W.G. Vascular injury: mechanisms and manifestations. Am J Med. 90(Suppl 4B):1991;8S-13S.
33. Fleckenstein-Grun G., Frey M., Thimm F., Fleckenstein A. Protective effects of various calcium antagonists against experimental arteriosclerosis. J Hum Hypertens. 6:1992;S13-S18.
34. Navarro-Estrada J.L., Oliveri R. Long-term efficacy of amlodipine in patients with severe coronary artery disease. J Cardiovasc Pharmacol. 22:1993;S24-S28.
35. Borhani N.O., Mercuri M., Borhani P.A.et al. Final outcome results of the multicenter isradipine diuretic atherosclerosis study (MIDAS) - A randomized controlled trial. J Am Med Assoc. 276:1996;785-791.
36. Orekhov A.N., Tertov V.V., Pivovarova E.M., Sobenin I.A., Akhmedzhanov N.M., Aronov D.M. Effect of amlodipine treatment on atherogenic properties of blood serum and low-density lipoprotein. J Cardiovasc Pharmacol. 26:1995;S25-S33.
37. Austin M.A., Breslow J.L., Hennekens C.H., Buring J.E., Willett W.C., Krauss R.M. Low density lipoprotein subclass patterns and risk of myocardial infarction. J Am Med Assoc. 260:1988;1917-1921.
38. Avogaro P., Bittolo Bon G., Cazzolato G. Presence of a modified low density lipoprotein in humans. Arteriosclerosis. 8:1988;79-87.
39. Esterbauer H., Striegl G., Puhl H., Rothender M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun. 6:1989;67-75.
40. Esterbauer H., Gebicki J., Puhl H., Juergens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radical Biol Med. 13:1992;341-390.
41. Yla-Herttuala S., Palinski W., Rosenfeld M.E.et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 84:1989;1086-1095.
42. Hoff H.F., O'Neil J. Lesion-derived low density lipoprotein and oxidized low density lipoprotein share a lability for aggregation, leading to enhanced macrophage degradation. Arterioscler Thromb. 11:1991;1209-1222.
43. Tertov V.V., Sobenin I.A., Gabbasov Z.A.et al. Three types of naturally occurring modified lipoproteins induce intracellular lipid accumulation due to lipoprotein aggregation. Circ Res. 71:1992;218-228.